Curative and organ-preserving treatment with intra-arterial carboplatin induction followed by surgery and/or radiotherapy for advanced head and neck cancer: single-center five-year results.

Szczegóły
Abstrakt

Tytuł:: Curative and organ-preserving treatment with intra-arterial carboplatin induction followed by surgery and/or radiotherapy for advanced head and neck cancer: single-center five-year results.
Autorzy:: Bertino G; Department of Otolaryngology, University of Pavia--IRCCS Policlinico S Matteo, Pavia, Italy. />Benazzo M
Gatti P
Bernardo G
Corbella F
Tinelli C
Zappoli F
Mira E
Źródło:: BMC cancer [BMC Cancer] 2007 Apr 11; Vol. 7, pp. 62. Date of Electronic Publication: 2007 Apr 11.
Typ publikacji:: Clinical Trial; Journal Article
Język:: English
Imprint Name(s):: Original Publication: London : BioMed Central, [2001-
MeSH Terms:: Antineoplastic Agents/*therapeutic use
Carboplatin/*therapeutic use
Carcinoma, Squamous Cell/*drug therapy
Head and Neck Neoplasms/*drug therapy
Adult ; Aged ; Antineoplastic Agents/administration & dosage ; Antineoplastic Agents/adverse effects ; Carboplatin/administration & dosage ; Carboplatin/adverse effects ; Carcinoma, Squamous Cell/radiotherapy ; Carcinoma, Squamous Cell/surgery ; Disease-Free Survival ; Dose-Response Relationship, Drug ; Female ; Follow-Up Studies ; Head and Neck Neoplasms/radiotherapy ; Head and Neck Neoplasms/surgery ; Humans ; Infusions, Intra-Arterial ; Male ; Middle Aged ; Treatment Outcome
References:: J Craniomaxillofac Surg. 2002 Apr;30(2):112-20. (PMID: 12069515)
Curr Opin Oncol. 2002 May;14(3):323-9. (PMID: 11981279)
J Clin Oncol. 2003 Jan 15;21(2):320-6. (PMID: 12525525)
Br J Cancer. 2004 Apr 5;90(7):1323-8. (PMID: 15054449)
Cancer Treat Rev. 1985 Sep;12 Suppl A:1-19. (PMID: 3910215)
Cancer Treat Rev. 1985 Sep;12 Suppl A:43-9. (PMID: 3910221)
Cancer Treat Rev. 1985 Sep;12 Suppl A:51-7. (PMID: 3910222)
Arch Otolaryngol Head Neck Surg. 1989 Jun;115(6):695-8. (PMID: 2655667)
N Engl J Med. 1991 Jun 13;324(24):1685-90. (PMID: 2034244)
Head Neck. 1992 Sep-Oct;14(5):364-71. (PMID: 1399569)
J Clin Oncol. 1994 Oct;12(10):2113-20. (PMID: 7931481)
Arch Otolaryngol Head Neck Surg. 1996 Aug;122(8):853-7. (PMID: 8703389)
Acta Otorhinolaryngol Ital. 1996 Feb;16(1):30-4. (PMID: 8984837)
Int J Radiat Oncol Biol Phys. 1997 May 1;38(2):263-71. (PMID: 9226312)
Head Neck. 2005 Jan;27(1):15-21. (PMID: 15515158)
J Clin Oncol. 2005 Mar 1;23(7):1447-54. (PMID: 15735120)
Lancet. 2000 Mar 18;355(9208):949-55. (PMID: 10768432)
Eur Arch Otorhinolaryngol. 2000;257(5):279-82. (PMID: 10923944)
Head Neck. 2000 Oct;22(7):687-93. (PMID: 11002324)
Br J Cancer. 2000 Dec;83(12):1594-8. (PMID: 11189100)
Arch Otolaryngol Head Neck Surg. 2001 Jul;127(7):809-12. (PMID: 11448355)
Head Neck. 2001 Sep;23(9):713-7. (PMID: 11505479)
Cancer Control. 2002 Sep-Oct;9(5):387-99. (PMID: 12410178)
Substance Nomenclature:: 0 (Antineoplastic Agents)
BG3F62OND5 (Carboplatin)
Entry Date(s):: Date Created: 20070413 Date Completed: 20070501 Latest Revision: 20181113
Update Code:: 20240104
PubMed Central ID:: PMC1854908
DOI:: 10.1186/1471-2407-7-62
PMID:: 17428336
: Czasopismo naukowe

Pełny tekst

Background: This study evaluated the feasibility, toxicity, response rate and survival of neoadjuvant superselective intra-arterial infusion of high dose carboplatin in advanced head and neck cancer.
Methods: Forty-six patients with primary head and neck squamous cell carcinoma received 3 cycles of intra-arterial carboplatin (300 to 350 mg/m2 per cycle every 2 weeks), followed by radiotherapy or surgery plus radiotherapy.
Results: No complications or severe toxicity occurred. Sixteen patients (35%) were complete responders, 20 (43%) partial responders while 10 (22%) did not respond to treatment. After completion of the multimodality treatment, 38/46 patients (83%) were complete responders. After a 5-year follow-up period, 18/46 patients (39%) are alive and disease-free, 3 (6,5%) have died of a second primary tumor and 25 (54.5%) have died of the disease.
Conclusion: Intra-arterial carboplatin induction chemotherapy is a safe, well-tolerated technique that discriminates between responders and non-responders and so may have prognostic significance in planning further integrated treatments aimed to organ preservation for advanced head and neck carcinomas.

Informacja